Richard Baffarin

Richard Baffarin asked for an update on Corelia's drug candidate progress towards an IND application and inquired about the valuation range being discussed with potential investors for the subsidiary.

Answer

CEO Rob Brainin stated that Champions Oncology has not publicly shared specific details regarding Corelia's IND progress or valuation. He expressed excitement about the data and the traction gained with venture capital partners, promising to share more meaningful information once available.

Richard Baffarin, a Private Investor, asked for an update on Corelia's drug candidates, specifically how far along they are before filing an IND application. He also requested a valuation range that investors are considering for Corelia.

Answer

CEO Rob Brainin stated that Champions Oncology has not publicly shared specific information about Corelia's drug candidate progress or valuation. He did express excitement about the data being generated and the traction gained with venture capital partners, promising to share more meaningful updates when available.